Investigating APG-157 for treating oral dysplasia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial aims to evaluate the safety and efficacy of APG-157 in reducing tumor size in patients with oral dysplasia and carcinoma in situ. Participants will undergo treatment with APG-157 while their tumor markers and oral rinses will be monitored. The study focuses on adults with biopsy-proven moderate to severe oral dysplasia or visible lesions in the oral cavity or oropharynx. The trial will assess measurable disease and the biological effects of the treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adult patients age \> 18 years with biopsy-proven moderate to severe oral dysplasia or carcinoma in situ (CIS) and a visible lesion. Sites include all oral cavity as well as oropharyngeal dysplasia that is accessible in the outpatient clinic.
2. Histologically proven oral cavity or oropharyngeal moderate or severe dysplasia/CIS as diagnosed by standard pathological methods and a visible lesion on oral exam.
3. Measurable disease - minimum lesion size of 8 x 3 mm before initial biopsy
4. Willing to provide blood, oral rinse and tissue from diagnostic biopsies
5. Leukocytes \>=3,000/microliter
6. Absolute neutrophil count \>= 1,000/microliter, Platelets \>= 100,000/microliter, Total bilirubin =\< 1.5 x institutional upper limit of normal (ULN), aspartate aminotransferase (AST), serum glutamic-oxaloacetic transaminase (SGOT), alanine aminotransferase (ALT) and serum glutamic pyruvic transaminase (SGPT) =\< 1.5 x institutional upper limit of normal (ULN). Exceptions to this Inclusion Criteria can be made if labs are deemed not clinically significant by the principal investigator (PI).
7. Willing to use adequate contraception, subject or partner has had a vasectomy or partner is using effective birth control or is post-menopausal for the duration of the study.
8. Able to take oral medication.
9. Able to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

1. Pregnant women.
2. Subjects who have had surgery of the oral cavity, teeth, or gums within the previous 8 weeks excluding biopsies and tooth extractions.
3. Subjects who have had a fracture of the mandible or maxilla within the previous 8 weeks.
4. Inability to complete enrollment forms due to any mental status or language problems (e.g. dementia, head injury, overall illness).
5. History of prior head and neck squamous cell carcinomas (HNSCC) unless curatively treated 1 year or more prior.
6. Use of chemotherapy and/or radiation for any malignancy (excluding nonmelanoma skin cancer and cancer confined to organs with removal as only treatment) in the past 2 years.
7. Subjects with other related diseases or the oral cavity or oropharynx, as determined to be significant by the PI.
8. History of allergic reactions attributed to compounds of similar chemical composition to Curcumin (turmeric).
9. Active or chronic liver disease, evidence of hepatitis (infectious or autoimmune), cirrhosis or portal hypertension. Exceptions to this Exclusion Criteria can be made if patient status is deemed not clinically significant by the PI.
10. Severe thrombocytopenia increasing the risk of biopsy.
11. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, uncontrolled congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Where it's running

• University of Miami
  Miami, Florida, United States Recruiting

Study contacts

• Principal investigator: Elizabeth J Franzmann, MD — University of Miami
• Study coordinator: Elizabeth J Franzmann, MD
• Email: efranzman@med.miami.edu
• Phone: 305-243-5955

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating the risk of cancer in patients with oral lichen planus

  This study is looking to see how often oral lichen planus turns into cancer in patients over time and what factors might increase that risk.

  Recruiting Catholic University of the Sacred Heart · Roma · NCT06934863

• Neural links for real-world emotions in mood and anxiety

  Researchers are testing how real-life emotional moments relate to brain activity and stress responses in young adults with mood and anxiety symptoms, using smartphones, self-reports, tasks, and MRI.

  Recruiting University of Miami · Coral Gables, Florida · NCT07891624

• Lixumistat window of opportunity in newly diagnosed glioblastoma

  This study tests whether Lixumistat can benefit adults with newly diagnosed glioblastoma who are planned for surgical tumor removal.

  Recruiting Early Phase 1 University of Miami · Miami, Florida · NCT07884344

• Velocity-Loss Resistance Training in Parkinson's Disease

  This trial tests whether two velocity-loss resistance training thresholds (10% vs 30%) improve muscle strength, power, and daily function in older adults with Parkinson's disease.

  Recruiting University of Miami · Coral Gables, Florida · NCT07840508

• Noninvasive ear stimulation for HIV-related nerve pain

  This study tests a non-invasive ear stimulation device to see if it can help nerve pain in people with HIV who have HIV-associated peripheral neuropathy.

  Recruiting University of Miami · Miami, Florida · NCT07822932

• Brain-avoiding proton craniospinal irradiation for leptomeningeal metastases

  This study tests BRAVO pCSI, a proton therapy approach that avoids certain brain regions, to see if it helps adults with leptomeningeal metastases from solid tumors.

  Recruiting University of Miami · Miami, Florida · NCT07789912

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.